PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: A systematic review and meta-analysis of diagnostic accuracy

HYSTEROSCOPIC ENDOMETRIAL FOCAL RESECTION FOLLOWED BY LEVONORGESTREL INTRAUTERINE DEVICE INSERTION AS A FERTILITY SPARING TREATMENT OF ATYPICAL ENDOMETRIAL HYPERPLASIA AND EARLY ENDOMETRIAL CANCER. A RETROSPECTIVE STUDY

(2018) Pierluigi Giampaolino et al.   Journal of Minimally Invasive Gynecology

Loss of Bcl-2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment. A systematic review and meta-analysis

(2018) Antonio Travaglino et al.   ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA

UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer

(2018) Laura Hardy et al.   Cancers

PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis

(2018) Antonio Travaglino et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Endometrial hyperplasia and risk of coexistent cancer: WHO vs EIN criteria

(2018) Antonio Travaglino et al.   HISTOPATHOLOGY

BCL-2 and PAX2 Expressions in EIN which Had Been Previously Diagnosed as Non-Atypical Hyperplasia

(2017) Levent Trabzonlu et al.   PATHOLOGY & ONCOLOGY RESEARCH

PAX2 maintains the differentiation of mouse oviductal epithelium and inhibits the transition to a stem cell-like state

(2017) Kholoud Alwosaibai et al.   Oncotarget

PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer

(2016) D A Modi et al.   ONCOGENE

Synthesizing Evidence from Diagnostic Accuracy TEsts: the SEDATE guideline

(2016) A. Sotiriadis et al.   ULTRASOUND IN OBSTETRICS & GYNECOLOGY

Divergent Roles of PAX2 in the Etiology and Progression of Ovarian Cancer

(2015) E. M. Al-Hujaily et al.   Cancer Prevention Research

Pax2 Expression in Simultaneously Diagnosed WHO and EIN Classification Systems

(2015) Amy K. Joiner et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

(2013) Penny F. Whiting   ANNALS OF INTERNAL MEDICINE

Utility of PAX2 as a Marker for Diagnosis of Endometrial Intraepithelial Neoplasia

(2012) Charles M. Quick et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Biomarkers of progestin therapy resistance and endometrial hyperplasia progression

(2012) Kristen Upson et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Expression pattern of PAX2 in hyperplastic and malignant endometrium

(2012) Korhan Kahraman et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

PAX2 Loss by Immunohistochemistry Occurs Early and Often in Endometrial Hyperplasia

(2012) Kimberly H. Allison et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

RNA interference of pax2 inhibits growth of transplanted human endometrial cancer cells in nude mice

(2011) Li-Ping Zhang et al.   Chinese Journal of Cancer

PAX2 Distinguishes Benign Mesonephric and Mullerian Glandular Lesions of the Cervix From Endocervical Adenocarcinoma, Including Minimal Deviation Adenocarcinoma

(2010) Joseph T. Rabban et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Joint Loss of PAX2 and PTEN Expression in Endometrial Precancers and Cancer

(2010) N. M. Monte et al.   CANCER RESEARCH

Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen

(2008) Pamela L. Strissel et al.   INTERNATIONAL JOURNAL OF CANCER